International Drug Development Institute
International Drug Development Institute is recorded as a service provider in 31 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 31 trials · Latest update first
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Sponsor NSABP Foundation Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Approximately 29% of screened patients (638/2,188) were screening failures.
- Slow enrollment prompted an amendment to revise statistical planning.
- Consistently low monthly EFS event rates in 2024 led to amendment of the analysis plan to permit definitive analysis at 242 rather than 252 confirmed EFS events.
- Following FDA approval of pembrolizumab for high-risk early-stage triple-negative breast cancer, 29 US patients discontinued neoadjuvant protocol therapy to initiate pembrolizumab without being counted as EFS events.
These findings describe the trial, not the service provider’s performance or responsibility.
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)
Sponsor Viridian Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Sponsor Alx Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-03)
Sponsor Alx Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for International Drug Development Institute?
The 2026-10-09 snapshot links International Drug Development Institute to 31 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Electronic data capture, Interactive response technology (IRT), among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for International Drug Development Institute?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Ophthalmology, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to International Drug Development Institute conducted?
The linked trials record locations in 25 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where International Drug Development Institute delivered services.
What can this page tell me about International Drug Development Institute's trial experience?
Browse 31 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under International Drug Development Institute. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- International Drug Development Institute
- International Drug Development Institute Inc.